{"nctId":"NCT00518323","briefTitle":"A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients","startDateStruct":{"date":"2007-08"},"conditions":["Schizophrenia"],"count":201,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone ER"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone ER"]},{"label":"003","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone ER"]},{"label":"004","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Paliperidone ER","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Paliperidone ER","otherNames":[]},{"name":"Paliperidone ER","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) criteria for schizophrenia (295.10, 295.20, 295.30, 295.60, 295.90) for 1 year (the diagnosis will be established using the K-SADS-PL, including all supplements)\n* Must not be a danger to themselves or others, and must have family support available to be maintained as an outpatient\n* Should have had at least 1 adequate treatment with an antipsychotic before participation in this study\n* Must have a PANSS score between 60 and 120, inclusive, at screening and baseline\n* Weight \\>=29 kg\n\nExclusion Criteria:\n\n* Meet the DSM-IV criteria at screening for dissociative disorder, bipolar disorder, major depressive disorder, schizoaffective disorder, schizophreniform disorder, autistic disorder, or primary substance induced psychotic disorder. Other comorbid disorders e.g., attention-deficit hyperactivity disorder (ADHD) are allowed as long as the diagnosis of schizophrenia is the primary diagnosis and the comorbid disorders in the investigator's judgment do not require medication\n* Mild, moderate, or severe mental retardation (i.e., documented intelligence quotient \\[IQ\\] \\<70) established by previous IQ testing or history\n* Women who are pregnant (as confirmed by urine pregnancy test performed at screening or baseline), planning to become pregnant or are nursing\n* Have a known or suspected history of seizure disorder, or neuroleptic malignant syndrome, encephalopathic syndrome, tardive dyskinesia, or insulin dependent diabetes mellitus\n* Presence of any significant or unstable cardiovascular, respiratory, renal, hepatic, hematologic, endocrine, immunologic, or other systemic disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the PANSS Total Score From Baseline to the Last Postrandomization Assessment in the Double-blind Period of the Study.","description":"The Positive and Negative Syndrome Scale (PANSS) measures the severity of psychotic symptoms of schizophrenia. Scores range from 30 to 210, where 30=best and 210=worst. The change in PANSS total score for all eligible subjects was measured from the beginning of the study to the end.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":"16.31"},{"groupId":"OG001","value":"-17.3","spread":"14.33"},{"groupId":"OG002","value":"-13.8","spread":"15.74"},{"groupId":"OG003","value":"-7.9","spread":"20.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Clinical Global Impression-Severity (CGI-S) Scale","description":"The CGI-S rating scale was used to assess the severity of a subject's overall clinical condition. Scores range from 1 to 7, where 1=best and 7=worst.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null},{"groupId":"OG002","value":"-1.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Children's Global Assessment (CGAS) Score","description":"The CGAS score assesses psychological, social, and school functioning for children 6 to 17 years of age. Scores range from 1 to 100, where 100=best and 1=worst.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"10.72"},{"groupId":"OG001","value":"13.1","spread":"12.07"},{"groupId":"OG002","value":"8.6","spread":"11.18"},{"groupId":"OG003","value":"5.0","spread":"13.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Sleep Visual Analog Scale (VAS) for Quality of Sleep.","description":"The sleep VAS for sleep quality is a scale for measuring the quality of sleep experienced by a patient. Scores range from 0 to 100, where 100=best and 0=worst.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"24.57"},{"groupId":"OG001","value":"16.0","spread":"27.06"},{"groupId":"OG002","value":"14.4","spread":"22.72"},{"groupId":"OG003","value":"-0.3","spread":"34.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Sleep VAS for Daytime Drowsiness","description":"The sleep VAS for daytime drowsiness is a scale for measuring the drowsiness experienced by a patient. Scores range from 0 to 100, where 100=best and 0=worst.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"24.69"},{"groupId":"OG001","value":"-7.2","spread":"25.22"},{"groupId":"OG002","value":"1.0","spread":"29.55"},{"groupId":"OG003","value":"-2.8","spread":"30.27"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":54},"commonTop":["Insomnia","Somnolence","Headache","Akathisia","Vomiting"]}}}